Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01125137 · ClinicalTrials.gov registry record · NA
Case-control Study on Matrix Metalloproteinase Levels in Tissue in Patients With Keloid Scar
A NA study, sponsored by Henry Ford Health System.
- Completed
- Registry status
- NA
- Development phase
- 20
- Enrollment target
NCT01125137 is a NA study that has completed, run by Henry Ford Health System. The registered enrollment target is 20 participants.
The verdict
NCT01125137, a NA study, has completed, sponsored by Henry Ford Health System.
- COMPLETED
- Registry status
- NA
- Development phase
- 20 participants
- Enrollment target
Study Summary
Purpose: To compare the levels of matrix metalloproteinase-1 (MMP-1), MMP-8, MMP-13 and tissue inhibitor of metalloproteinases (TIMPs) in keloid skin tissue with normal skin in the same patient and with normal discarded skin tissue (control). The investigators aim to correlate between levels of MMPs in patients with keloid scarring in comparison with normal and discarded tissue.
Interventions
- PROCEDURE Removal of Keloid
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2010-02 |
| Est. Completion | 2011-01 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01125137
The ClinicalTrials.gov registry entry for NCT01125137 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Henry Ford Health System, which has 234 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Removal of Keloid is the first listed.
NCT01125137 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01125137 about?
NCT01125137 is a clinical study titled "Case-control Study on Matrix Metalloproteinase Levels in Tissue in Patients With Keloid Scar". Purpose: To compare the levels of matrix metalloproteinase-1 (MMP-1), MMP-8, MMP-13 and tissue inhibitor of metalloproteinases (TIMPs) in keloid skin tissue with normal skin in the same patient and with normal discarded skin tissue (control). The investigators aim to correlate between levels of MMP...
What is the current status of trial NCT01125137?
This trial is currently completed. It is a NA study. The enrollment target is 20 participants. The study started on 2010-02. Estimated completion is 2011-01.
What interventions are being tested in trial NCT01125137?
The interventions under investigation include: Removal of Keloid (PROCEDURE).
Who is sponsoring clinical trial NCT01125137?
This trial is sponsored by Henry Ford Health System, which has 234 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.